Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obeldesivir for Postexposure Prophylaxis of Filovirus Diseases
NCT06682234Phase 2Withdrawn
- Sponsor
- Gilead Sciences
- Start
- Dec 2025
- Primary completion
- Dec 2025
- Modality
- Prodrugs/Conditional Activator Small Molecules
01
Overview
A Phase 2 trial of obeldesivir in Filovirus Hemorrhagic Fever, sponsored by Gilead Sciences. Planned start Dec 2025; status: withdrawn.
02
Drugs
obeldesivir
03
Conditions
Filovirus Hemorrhagic Fever
Beyond the preview
Go deeper on NCT06682234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06682234.